Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

Trial ID or NCT#

NCT00373347

Status

recruiting iconRECRUITING

Purpose

The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)

Official Title

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. - Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. - Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
Exclusion Criteria:
  1. -Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
View All Criteria
Show Less

Investigator(s)

Samuel So, MD
Samuel So, MD
Surgical oncologist, Liver surgeon, General surgeon
Lui Hac Minh Professor in the School of Medicine

Contact us to find out if this trial is right for you.

Contact

Mei-Sze Chua
650-724-3525

SEND MESSAGE

View on ClinicalTrials.gov